Douglas M. Willis

Array ( [id] => 16533249 [patent_doc_number] => 10875832 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-29 [patent_title] => Substituted pyrimidines for treating bacterial infections [patent_app_type] => utility [patent_app_number] => 16/512245 [patent_app_country] => US [patent_app_date] => 2019-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 29516 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16512245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15038329 [patent_doc_number] => 20190330169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => SELECTIVE HDAC1,2 INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/507727 [patent_app_country] => US [patent_app_date] => 2019-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29803 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16507727 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15711095 [patent_doc_number] => 20200102313 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/460755 [patent_app_country] => US [patent_app_date] => 2019-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38311 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16460755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17865013 [patent_doc_number] => 20220287748 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY [patent_app_type] => utility [patent_app_number] => 17/255843 [patent_app_country] => US [patent_app_date] => 2019-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52175 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 234 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17255843 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15711111 [patent_doc_number] => 20200102321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C [patent_app_type] => utility [patent_app_number] => 16/449967 [patent_app_country] => US [patent_app_date] => 2019-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57739 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16449967 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14960533 [patent_doc_number] => 20190307744 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-10 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING CLOFAZIMINE ANALOG COMPOUND B746 OR CLOFAZIMINE ANALOG COMPOUND B826 [patent_app_type] => utility [patent_app_number] => 16/450939 [patent_app_country] => US [patent_app_date] => 2019-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13640 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16450939 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14929681 [patent_doc_number] => 20190300478 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS [patent_app_type] => utility [patent_app_number] => 16/444781 [patent_app_country] => US [patent_app_date] => 2019-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49542 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16444781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16756538 [patent_doc_number] => 10975074 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-13 [patent_title] => Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines [patent_app_type] => utility [patent_app_number] => 16/440424 [patent_app_country] => US [patent_app_date] => 2019-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 41 [patent_no_of_words] => 56044 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 790 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16440424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15070925 [patent_doc_number] => 10464938 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-05 [patent_title] => Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof [patent_app_type] => utility [patent_app_number] => 16/439361 [patent_app_country] => US [patent_app_date] => 2019-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20103 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16439361 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15239513 [patent_doc_number] => 20190374542 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => KRAS G12C INHIBITORS AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/438349 [patent_app_country] => US [patent_app_date] => 2019-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 149302 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16438349 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16756549 [patent_doc_number] => 10975085 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-13 [patent_title] => Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III [patent_app_type] => utility [patent_app_number] => 16/436195 [patent_app_country] => US [patent_app_date] => 2019-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56638 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 212 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16436195 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14867935 [patent_doc_number] => 20190284209 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES [patent_app_type] => utility [patent_app_number] => 16/425407 [patent_app_country] => US [patent_app_date] => 2019-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38995 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16425407 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16290086 [patent_doc_number] => 10766922 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-08 [patent_title] => Substituted steroids for the treatment of cancer [patent_app_type] => utility [patent_app_number] => 16/423205 [patent_app_country] => US [patent_app_date] => 2019-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 14331 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16423205 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15178043 [patent_doc_number] => 20190359613 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => TLR7 AGONISTS [patent_app_type] => utility [patent_app_number] => 16/422050 [patent_app_country] => US [patent_app_date] => 2019-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40234 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16422050 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15363477 [patent_doc_number] => 20200017503 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA [patent_app_type] => utility [patent_app_number] => 16/418558 [patent_app_country] => US [patent_app_date] => 2019-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31938 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16418558 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16428238 [patent_doc_number] => 10828299 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-10 [patent_title] => Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine [patent_app_type] => utility [patent_app_number] => 16/413458 [patent_app_country] => US [patent_app_date] => 2019-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 34648 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16413458 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15038367 [patent_doc_number] => 20190330188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => ENANTIOMERS OF 8-HYDROXYQUINOLINE DERIVATIVES AND THE SYNTHESIS THEREOF [patent_app_type] => utility [patent_app_number] => 16/410776 [patent_app_country] => US [patent_app_date] => 2019-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19597 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 448 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16410776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16290059 [patent_doc_number] => 10766895 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-08 [patent_title] => Preparation methods for palbociclib free base crystal form A and crystal form B [patent_app_type] => utility [patent_app_number] => 16/405722 [patent_app_country] => US [patent_app_date] => 2019-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 4523 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16405722 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14746721 [patent_doc_number] => 20190256534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => PROCESS FOR PREPARING TRIS[3-(DIALKYLALKOXYSILYL)PROPYL]ISOCYANURATES [patent_app_type] => utility [patent_app_number] => 16/404807 [patent_app_country] => US [patent_app_date] => 2019-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5921 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16404807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14867933 [patent_doc_number] => 20190284208 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => N-[(2,4-DIFLUOROPHENYL)METHYL]-6-HYDROXY-3-METHYL-5,7-DIOXO-2,3,5,7,11,11a-HEXAHYDRO[1,3]OXAZOLO[3,2-a]PYRIDO[1,2-d]PYRAZINE-8-CARBOXAMIDE HAVING HIV INTEGRASE INHIBITORY ACTIVITY [patent_app_type] => utility [patent_app_number] => 16/400373 [patent_app_country] => US [patent_app_date] => 2019-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40121 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16400373 [rel_patent_id] =>[rel_patent_doc_number] =>)